Extract notice to the Minister

Omlyclo (nouvelle teneur)

Common name / Subject : omalizumab
Name of the manufacturer : Celltrion
Form : Sol. Inj. S.C. (ser); Sol. Inj. S.C. (stylo)
Dosage : 150 mg/ml (2 ml)

Indication : Urticaire chronique idiopathique (nouvelle teneur)

INESSS' Recommendation
Inscription – Sous conditions 

Minister's decisions
À venir

Evaluation published on April 29, 2026

INESSSid: 29914
Recevable on February 02, 2026

Download Advice to minister about Omlyclo (nouvelle teneur)

Extrait d'avis à la ministre sur Omlyclo 354 KiO

Subscribe to our newsletter now

Subscription